Therapeutic approaches to modulating Notch signaling: Current challenges and future prospects
- 30 June 2012
- journal article
- review article
- Published by Elsevier BV in Seminars in Cell & Developmental Biology
- Vol. 23 (4), 465-472
- https://doi.org/10.1016/j.semcdb.2012.01.016
Abstract
No abstract availableKeywords
Funding Information
- NIH (R01 GM087650)
- National Institute of General Medical Sciences (NIGMS)
- Thomas Jefferson University Department of Biochemistry
This publication has 94 references indexed in Scilit:
- Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myelomaCellular Oncology, 2011
- Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ‐secretase inhibitor targeting notch signalingPediatric Blood & Cancer, 2011
- Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrenceBritish Journal of Cancer, 2011
- GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemiaLeukemia, 2011
- Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm ShiftNeuron, 2011
- Direct inhibition of the NOTCH transcription factor complexNature, 2009
- Inhibition of γ-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal AdenocarcinomaGastroenterology, 2009
- γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemiaNature Medicine, 2008
- Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemiaNature Medicine, 2007
- Notch-induced T cell development requires phosphoinositide-dependent kinase 1The EMBO Journal, 2007